Drug Profile
RDX 023
Alternative Names: NTX023-1; RDX-023; RDX023-2Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Ardelyx
- Class Heart failure therapies; Hepatoprotectants; Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal disorders; Heart failure; Kidney disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Non-alcoholic steatohepatitis in USA (PO) (Ardelyx pipeline, September 2023)
- 04 Sep 2023 Discontinued for Gastrointestinal disorders in USA (PO) (Ardelyx pipeline, September 2023)
- 04 Sep 2023 Discontinued for Heart failure in USA (PO) (Ardelyx pipeline, September 2023)